You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma

Alerts

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address